India, Aug. 4 -- On Tuesday, Nuvectis Pharma, Inc. (NVCT), a clinical stage biopharma company, reported wider loss in the second quarter of 2026 due to higher costs
On the Nasdaq, the shares were trading 7.06 percent down at $20.08.
Net loss attributable to the common shareholders for the period widened to $7.02 million from $6.33 million in the same quarter last year. On a per share basis, loss was $0.30, in line with the prior year.
Operating loss for the period widened to $7.20 million, from $6.60 million in the previous year.
googletag.cmd.push(function() { googletag.display('div-gpt-ad-1568189509843-0'); });
Research and Development costs rose to $4.68 million from $3.61 million a year ago.
General and Administrative expenses, on...